A drug candidate created with AI reduced biological age markers across 6 proteomic clocks in a phase 2a trial, suggesting ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible resultsSome results have been hidden because they may be inaccessible to you
Show inaccessible results